LT-010366 / Shanghai Leadingtac Pharma - LARVOL DELTA

LT-010366, a first-in-class orally bioavailable KRAS G12D degrader in the treatment of multiple KRAS G12D-mutated cancer models in vitro and in vivo (AACR 2025) - "In summary, our results demonstrated that LT-010366 induced degradation of KRAS G12D protein, inhibition of KRAS downstream signaling mediators and exhibited antitumor activity in multiple KRAS G12D-mutated cancer cells in vitro and in vivo. LT-010366 is a promising therapeutic agent to be advanced to clinical development for patients with tumors harboring KRAS G12D mutation."

Preclinical • Colorectal Cancer • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • HRAS • KRAS • NRAS